Reuters logo
BRIEF-Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma
November 13, 2017 / 7:34 AM / 10 days ago

BRIEF-Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma

Nov 13 (Reuters) - PHARMA MAR SA:

* PRESENTS POSITIVE RESULTS FROM A PHASE II STUDY OF LURBINECTEDIN IN EWING´S SARCOMA

* OBSERVED DISEASE CONTROL RATE AT 60 PERCENT, INCLUDING PARTIAL RESPONSES IN 12 PERCENT AND STABILIZATION IN 48 PERCENT OF CASES ‍​ Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below